Nurix Therapeutics (NRIX) Expected to Announce Earnings on Wednesday

Nurix Therapeutics (NASDAQ:NRIX) is expected to release its earnings data before the market opens on Wednesday, April 9th. Analysts expect Nurix Therapeutics to post earnings of ($0.72) per share and revenue of $12.78 million for the quarter.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Stock Up 0.3 %

Shares of NASDAQ:NRIX opened at $9.72 on Tuesday. Nurix Therapeutics has a fifty-two week low of $8.60 and a fifty-two week high of $29.56. The firm’s 50-day simple moving average is $15.25 and its 200-day simple moving average is $19.75. The company has a market cap of $741.01 million, a price-to-earnings ratio of -3.36 and a beta of 2.23.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,811 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock valued at $213,449 in the last ninety days. Corporate insiders own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on NRIX shares. Stifel Nicolaus boosted their target price on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. dropped their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partners began coverage on Nurix Therapeutics in a research report on Monday, March 17th. They issued a “market perform” rating and a $16.00 price objective for the company. BTIG Research began coverage on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $35.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.88.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.